ABH 001

Drug Profile

ABH 001

Alternative Names: ABH-001; Dermagraft; Human fibroblast-derived dermal substitute

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Shire
  • Class Cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Epidermolysis bullosa
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Epidermolysis bullosa

Most Recent Events

  • 17 Jan 2014 Organogenesis acquires ABH 001 from Shire
  • 07 Oct 2013 Shire completes enrolment in its phase III trial for Epidermolysis bullosa in USA, Canada, Austria, France, Germany, Poland, Portugal & Spain (NCT01749306)
  • 30 Sep 2013 Discontinued - Phase-III for Epidermolysis bullosa in USA , Spain, Austria, Germany, Portugal, Canada, Poland and France (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top